Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NQG7

UPID:
HPS4_HUMAN

ALTERNATIVE NAMES:
Hermansky-Pudlak syndrome 4 protein; Light-ear protein homolog

ALTERNATIVE UPACC:
Q9NQG7; B1AHQ4; Q5H8V6; Q96LX6; Q9BY93; Q9UH37; Q9UH38

BACKGROUND:
HPS4, integral to the BLOC-3 complex, serves as a guanine exchange factor for RAB32 and RAB38, crucial for melanin synthesis and melanosome formation. This protein's function underscores its importance in the regulation of melanosome biogenesis and membrane localization of RAB32 and RAB38.

THERAPEUTIC SIGNIFICANCE:
Linked to Hermansky-Pudlak syndrome 4, HPS4's dysfunction manifests in oculocutaneous albinism, bleeding disorders, and lysosomal storage issues. Targeting HPS4's pathway offers a promising avenue for therapeutic intervention, especially for mitigating pulmonary fibrosis associated with the syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.